Skip to main content
main-content

Type 2 diabetes medications

Interactive patient case study

Hypoglycemia and technology

Hypoglycemia and technology

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

Get more on: Hypoglycemia | Devices and technology | Pediatric diabetes

medwireNews editor's pick

No fracture risk found with canagliflozin in real-world data

Cervical hip (femoral neck) fracture

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

medwireNews editor's pick

Real-world data show benefits of insulin degludec vs glargine in type 2 diabetes

Insulin pens

Insulin-naive adults with type 2 diabetes derive greater benefit from treatment with insulin degludec than from insulin glargine 300 units/mL, results from the US clinical practice-based CONFIRM study show.

Expert opinion editorial

Diabetes and obstructive sleep apnea syndrome: Double trouble

Sleep apnea (symbolic image with model)

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition [read more].

Get more on: Sleep disorders | Obesity | Type 2 diabetes complications

medwireNews editor's pick

Possible bile duct cancer risk with incretin-based medications

Mixed pills

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

medwireNews editor's pick

Older type 2 diabetes patients may derive greatest liraglutide benefits

Elderly diabetic patient (symbolic image with models)

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

medwireNews editor's pick

Research predicts ‘highly inadequate’ insulin access in coming years

Insulin pens

A modeling study predicts a greater than 20% increased need for insulin to treat patients with type 2 diabetes over the next 22 years, with implications for medication access.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

medwireNews

01-08-2019 | Dapagliflozin | News

Observational data hint at additional dapagliflozin benefits

A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.

01-07-2019 | Sitagliptin | News

Early sitagliptin initiation benefits patients uptitrating metformin

Patients with type 2 diabetes who are uptitrating to a maximum metformin dose benefit from improved glycemic control when they simultaneously initiate sitagliptin, randomized trial findings suggest.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-27-2018 | Insulin | Article

Insulin injection technique questionnaire: Results of an international study comparing Brazil, Latin America and World data

Calliari LE et al. Diabetol Metab Syndr 2018; 10: 85. doi: 10.1186/s13098-018-0389-3

11-15-2018 | Pregnancy | Article

Successful outcomes with insulin degludec in pregnancy: A case series

Hiranput S et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0532-z

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits